Works by Tseng, Ling-Ming

Results: 108
    1
    2

    Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

    Published in:
    Nature Communications, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41467-025-59210-6
    By:
    • Hu, Xichun;
    • Zhang, Qingyuan;
    • Sun, Tao;
    • Xiong, Huihua;
    • Li, Wei;
    • Teng, Yuee;
    • Lu, Yen-Shen;
    • Tseng, Ling-Ming;
    • Yan, Min;
    • Li, Hongsheng;
    • Pang, Danmei;
    • -Chen, Shin-Cheh;
    • Chen, Wenyan;
    • Jiang, Ou;
    • Wang, Jingfen;
    • Wu, Xinhong;
    • Wang, Xian;
    • Zang, Aimin;
    • Wang, Xiaojia;
    • Collins, Julie M.
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10

    Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.

    Published in:
    Breast Cancer Research, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s13058-023-01751-z
    By:
    • Cheng, Han-Fang;
    • Tsai, Yi-Fang;
    • Liu, Chun-Yu;
    • Hsu, Chih-Yi;
    • Lien, Pei-Ju;
    • Lin, Yen-Shu;
    • Chao, Ta-Chung;
    • Lai, Jiun-I.;
    • Feng, Chin-Jung;
    • Chen, Yen-Jen;
    • Chen, Bo-Fang;
    • Chiu, Jen-Hwey;
    • Tseng, Ling-Ming;
    • Huang, Chi-Cheng
    Publication type:
    Article
    11
    12
    13
    14
    15

    An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases.

    Published in:
    Supportive Care in Cancer, 2012, v. 20, n. 12, p. 3307, doi. 10.1007/s00520-012-1484-x
    By:
    • Zeng, Liang;
    • Chow, Edward;
    • Zhang, Liying;
    • Tseng, Ling-Ming;
    • Hou, Ming-Feng;
    • Fairchild, Alysa;
    • Vassiliou, Vassilios;
    • Jesus-Garcia, Reynaldo;
    • El-Din, Mohamed;
    • Kumar, Aswin;
    • Forges, Fabien;
    • Chie, Wei-Chu;
    • Bedard, Gillian;
    • Bottomley, Andrew
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Comprehensive Breast Cancer Adjuvant Digital Summary.

    Published in:
    Journal of Digital Imaging, 2006, v. 19, n. 3, p. 264, doi. 10.1007/s10278-006-0587-7
    By:
    • Liu, Jacqueline Ming;
    • Wu, Hsiao Wei;
    • Tiu, Chui Mei;
    • Tseng, Ling Ming;
    • Yen, Sang Hue;
    • Shiau, Cheng Ying;
    • Lan, Chieh;
    • Li, Anna Fen Yau
    Publication type:
    Article
    25
    26
    27
    28

    Predictive factors of overall quality of life in advanced cancer patients using EORTC QLQ-C30.

    Published in:
    Expert Review of Pharmacoeconomics & Outcomes Research, 2014, v. 14, n. 1, p. 139, doi. 10.1586/14737167.2014.864560
    By:
    • Cramarossa, Gemma;
    • Zeng, Liang;
    • Zhang, Liying;
    • Tseng, Ling-Ming;
    • Hou, Ming-Feng;
    • Fairchild, Alysa;
    • Vassiliou, Vassilios;
    • Jesus-Garcia, Reynaldo;
    • Alm El-Din, Mohamed A;
    • Kumar, Aswin;
    • Forges, Fabien;
    • Chie, Wei-Chu;
    • Sahgal, Arjun;
    • Lam, Henry;
    • Pulenzas, Natalie;
    • Chow, Edward
    Publication type:
    Article
    29

    Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.

    Published in:
    Journal of Cellular Physiology, 2012, v. 227, n. 3, p. 976, doi. 10.1002/jcp.22806
    By:
    • Yang, Yi-Ping;
    • Chang, Yuh-Lih;
    • Huang, Pin-I;
    • Chiou, Guang-Yuh;
    • Tseng, Ling-Ming;
    • Chiou, Shih-Hwa;
    • Chen, Ming-Hsiung;
    • Chen, Ming-Teh;
    • Shih, Yang-Hsin;
    • Chang, Chin-Hong;
    • Hsu, Chuan-Chih;
    • Ma, Hsin-I;
    • Wang, Chin-Tien;
    • Tsai, Lo-Lin;
    • Yu, Cheng-Chia;
    • Chang, Charn-Jung
    Publication type:
    Article
    30
    31
    32
    33

    Anti-tumor efficacy of a bevacizumab preconditioning followed by etoposide and cisplatin regimen in human epidermal growth factor receptor-2-positive breast cancer brain metastasis refractory to whole brain radiotherapy.

    Published in:
    Journal of Cancer Research & Practice, 2023, v. 10, n. 1, p. 11, doi. 10.4103/ejcrp.eJCRP-D-23-00001
    By:
    • Chen, Tom;
    • Lin, Ching-Hung;
    • Yeh, Dah-Cherng;
    • Tseng, Ling-Ming;
    • Rau, Kun-Ming;
    • Chen, Bang-Bin;
    • Chao, Ta-Chung;
    • Huang, Shu-Min;
    • Chang, Dwan-Ying;
    • Chen, I-Chun;
    • Cheng, Ann-Lii;
    • Lu, Yen-Shen
    Publication type:
    Article
    34

    Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study

    Published in:
    Oncology Research & Treatment, 2024, v. 47, n. 10, p. 484, doi. 10.1159/000540369
    By:
    • Tseng, Ling-Ming;
    • Chen, Fang Ming;
    • Chen, Shou-Tung;
    • Cheng, Fiona Tsui-Fen;
    • Chao, Tsu-Yi;
    • Dai, Ming-Shen;
    • Kao, Woei-Yau;
    • Yeh, Ming-Hsin;
    • Chen, Dar-Ren;
    • Liu, Liang-Chih;
    • Wang, Hewi Chung;
    • Chang, Hong-Tai;
    • Wang, Being Whey;
    • Yu, Jyh-Cherng;
    • Chen, Shin Cheh;
    • Liao, Guo-Shiou;
    • Hou, Ming-Feng
    Publication type:
    Article
    35
    36
    37
    38
    39
    40
    41
    42
    43

    Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).

    Published in:
    BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11291-6
    By:
    • Kuo, Sung-Hsin;
    • Tseng, Ling-Ming;
    • Chen, Shou-Tung;
    • Sagara, Yasuaki;
    • Chang, Yuan-Ching;
    • Yeh, Hsien-Tang;
    • Kuo, Yao-Lung;
    • Hung, Chih-Chiang;
    • Lu, Tzu-Pin;
    • Lee, Yi-Hsuan;
    • Toi, Masakazu;
    • Huang, Chiun-Sheng
    Publication type:
    Article
    44

    Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer.

    Published in:
    Cancer Science, 2024, v. 115, n. 9, p. 3079, doi. 10.1111/cas.16234
    By:
    • Iwata, Hiroji;
    • Xu, Binghe;
    • Kim, Sung‐Bae;
    • Chung, Wei‐Pang;
    • Park, Yeon Hee;
    • Kim, Min Hwan;
    • Tseng, Ling‐Ming;
    • Chung, Chi‐Feng;
    • Huang, Chiun‐Sheng;
    • Kim, Jee Hyun;
    • Chiu, Joanne Wing Yan;
    • Yamashita, Toshinari;
    • Li, Wei;
    • Egorov, Anton;
    • Nishijima, Soichiro;
    • Nakatani, Shunsuke;
    • Nishiyama, Yuji;
    • Sugihara, Masahiro;
    • Cortés, Javier;
    • Im, Seock‐Ah
    Publication type:
    Article
    45
    46
    47
    48
    49

    Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2−, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study.

    Published in:
    Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241286775
    By:
    • Zhang, Qingyuan;
    • Shen, Kunwei;
    • Song, Chuan-gui;
    • Ouyang, Quchang;
    • Liu, Zhenzhen;
    • Liu, Qiang;
    • Feng, Jifeng;
    • Chiu, Joanne W. Y.;
    • Tang, Jinhai;
    • Jiang, Zefei;
    • Tseng, Ling-Ming;
    • Wang, Xiaojia;
    • Yang, Liu;
    • Qian, Chenxi;
    • Shao, Zhimin
    Publication type:
    Article
    50